U.S. markets closed

CymaBay Therapeutics, Inc. (CBAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.7200+0.0900 (+1.94%)
At close: 4:00PM EDT
4.8200 +0.10 (2.12%)
After hours: 04:42PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.6300
Open4.6400
Bid4.6900 x 4000
Ask4.8400 x 3200
Day's Range4.5700 - 4.8400
52 Week Range3.1600 - 9.0600
Volume662,183
Avg. Volume800,860
Market Cap325.66M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-0.8050
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.64
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021
    GlobeNewswire

    CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021

    New analyses adds to the growing body of evidence for seladelpar’s potential as a treatment for patients with PBC NEWARK, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced positive data from its previously completed Phase 2 study and the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangi

  • CymaBay Therapeutics to Present at Upcoming Investor Conferences
    GlobeNewswire

    CymaBay Therapeutics to Present at Upcoming Investor Conferences

    NEWARK, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual investor conferences including SVB Leerink CybeRx Series: “Liver Disease Day” Conference taking place June 17, 2021, the Raymond James Human Health Innovation Conference taking place June 22, 2021 and the Pi

  • CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2021
    GlobeNewswire

    CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2021

    NEWARK, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be delivered during The International Liver Congress™ 2021 of the European Association for the Study of Liver (EASL) which will be held online June 23rd – 26th. A presentation1 will be made highlighting the effica